Today: 6 November 2025
Subscribe
Browse Tag

clinical trials

Femasys (FEMY) Skyrockets on Breakthrough Birth Control Trial News – Is This Women’s Health Innovator a Game-Changer?

Femasys (FEMY) Skyrockets on Breakthrough Birth Control Trial News – Is This Women’s Health Innovator a Game-Changer?

Company Overview – Innovating in Women’s Health Femasys Inc. is a Georgia-based medical device and biotherapeutics company specializing in women’s reproductive health solutions. Founded and led by CEO Kathy Lee-Sepsick (a female inventor-entrepreneur), Femasys aims to “transform women’s healthcare” by addressing long-neglected needs with non-surgical, in-office technologies femasys.com gurufocus.com. The company’s mission is to provide women with minimally invasive, office-based alternatives that improve patient care and reduce costs, in areas ranging from infertility to contraception and cancer diagnostics femasys.com gurufocus.com. Safety and accessibility are emphasized – Femasys notes that advances in female reproductive health are “long overdue,” and its products
3 November 2025
 ·  ·  ·  ·  · 
Biotech Boom: Cabaletta Bio’s CAR-T Trial Sparks 40% Stock Surge

Biotech Boom: Cabaletta Bio’s CAR-T Trial Sparks 40% Stock Surge

Stock Performance & Technical Indicators Cabaletta’s stock has been very volatile. From ~$2.40 on Oct 27 (post-data) it briefly dipped to the $2.47 area by Oct 30, then exploded higher on Oct 31. Benzinga notes that CABA “rose 36.6% to $3.38” intraday on Oct 31 benzinga.com; it eventually closed at $3.61 stockanalysis.com. Over the week of Oct 25–31, CABA gained ~37% tradingview.com. For perspective, its 52-week range is roughly $0.99–$5.46 stockanalysis.com. Technically, the stock is strongly overbought after the rally. On Oct 31 the 14-day RSI was ~84 investing.com (above 70 = overbought). All short-term moving averages (5d, 10d, 20d)
31 October 2025
 ·  ·  ·  · 
Tiny Biotech INTENSITY THERAPEUTICS Stock Skyrockets on Cancer Therapy Breakthrough – Experts See Big Upside

Biotech Bombshell: Intensity Therapeutics (INTS) Surges Nearly 400% on Major Cancer Trial News

Stock Performance & Recent Market Reaction Intensity Therapeutics shares were flat-to-down during Oct. 2025 until the news, trading around $0.27 on Oct. 29 ts2.tech. On Oct. 30 (Thursday), publication of its trial in Lancet sent the stock parabolic: intraday it soared nearly 395%, closing at $1.32 benzinga.com. In after-hours trading, the stock gave up much of the gain and traded around $0.90 by the end of Thursday benzinga.com. (Benzinga reported a 31.9% after-hours decline benzinga.com.) A massive volume surge accompanied the move – hundreds of millions of shares changed hands (compared to ~5 million normally) ts2.tech. Despite this spike, INTS
31 October 2025
 ·  ·  ·  ·  · 
Intellia Therapeutics Stock Plummets 45% After CRISPR Trial Shock – Can Gene-Editing Hopes Survive?

Intellia Therapeutics Stock Plummets 45% After CRISPR Trial Shock – Can Gene-Editing Hopes Survive?

CRISPR Trial Halt Triggers Sell-Off Intellia’s stock was hammered on Monday after the biotech stunned investors with news of a clinical trial pause. Before the opening bell, the Cambridge, MA-based company announced it had temporarily halted patient dosing and screening in two late-stage trials of its in vivo CRISPR treatment nexiguran ziclumeran (NTLA-2001) due to a serious adverse event reuters.com. A patient in the Phase 3 MAGNITUDE study – which tests NTLA-2001 in transthyretin amyloidosis patients with cardiomyopathy (ATTR-CM) – experienced Grade 4 elevations in liver enzymes and bilirubin after receiving the one-time gene therapy reuters.com ca.investing.com. This met the trial’s pre-specified safety
27 October 2025
 ·  ·  ·  · 
RNA Stock Skyrockets: Avidity Biosciences Soars on $12B Novartis Buyout and Breakthrough Trials

RNA Stock Skyrockets: Avidity Biosciences Soars on $12B Novartis Buyout and Breakthrough Trials

Stock Performance & Recent Trends Prior to the buyout news, RNA stock had been on a steady uptrend in 2025. The share price more than doubled from the low-$20s a year ago to the high-$40s this month ts2.tech. In the past three months alone, RNA jumped ~40%, fueled by upbeat clinical updates and M&A speculation ts2.tech. The stock hit a 52-week peak of $56 in early October ts2.tech after its lead DMD therapy showed strong results and secured FDA Breakthrough designation. Shares pulled back slightly to around $49 by late October, but remained up 100%+ year-over-year ts2.tech. A major catalyst
27 October 2025
 ·  ·  ·  ·  ·  · 
Theriva Biologics (TOVX) Stock Soars 92% on Oncolytic Virus Trial News – Can the Rally Last?

Theriva Biologics (TOVX) Stock Surges on Cancer Trial Breakthrough – What’s Next?

Theriva’s Stock Swing: In mid-October, Theriva’s Nasdaq-traded shares spiked on news of clinical success. On Oct. 15 the stock jumped from roughly $0.44 to $0.84 intraday ts2.tech, an increase of about 92%. This surge coincided with reports that VCN-01 had met the primary endpoints in the VIRAGE Phase 2b trial (see below). The very next trading day, Theriva disclosed a $4.0 million warrant inducement financing. Investors exercising warrants at $0.54 per share provided immediate cash ts2.tech, but the announcement also trimmed the earlier stock rally – TOVX settled in the mid-$0.40 range by Oct. 16 ts2.tech ts2.tech. In the days
24 October 2025
 ·  ·  ·  ·  · 
Neuphoria Stock Crashes After Social Anxiety Trial Failure — What’s Next?

Neuphoria Stock Crashes After Social Anxiety Trial Failure — What’s Next?

Key Facts: – Neuphoria (Nasdaq: NEUP) shares plunged ~67% in after-hours trading on Oct 20 when its lead drug BNC210 failed a Phase 3 SAD trial investing.com. The AFFIRM-1 trial missed both primary and secondary endpoints, and the company immediately halted its social anxiety program and launched a full strategic review investing.com globenewswire.com. – CEO Spyros Papapetropoulos vowed to “conserve our cash position” while exploring options to “maximize value for shareholders” globenewswire.com. Neuphoria will evaluate BNC210 in PTSD (where earlier data were promising) and otherwise cut spending. – NEUP stock fell from about $15.40 on Oct 20 to roughly $5
24 October 2025
 ·  ·  ·  ·  · 
Reviva Pharma Rockets 28% on Schizophrenia Trial Win – Analysts Eye 1000% Upside

Reviva Pharma Rockets 28% on Schizophrenia Trial Win – Analysts Eye 1000% Upside

As of Oct 24, 2025, RVPH shares trade around $0.57 investing.com, after a volatile October run (ranging roughly $0.26–$0.84). The stock has surged ~28% on Oct 23 (to $0.5675 markets.financialcontent.com) after a prior drop (–23% on Oct 8 benzinga.com). Recent catalysts include completion of a 1-year Phase 3 trial (brilaroxazine OLE) showing robust, sustained efficacy revivapharma.com, and plans for an FDA meeting in Q4 2025 toward a 2026 NDA revivapharma.com. Reviva also raised capital via equity offerings (~$10M in Q2 and ~$9M in Sept revivapharma.com revivapharma.com) to fund its CNS pipeline. Analysts remain extremely bullish – consensus is “Strong Buy”
24 October 2025
 ·  ·  ·  ·  · 
Inhibrx Biosciences Stock Soars on Breakthrough Cancer Trial News

Inhibrx Biosciences Stock Soars on Breakthrough Cancer Trial News

Breakthrough Trial Results in Rare Bone Cancer Inhibrx’s lead drug, ozekibart, achieved a landmark win in its ChonDRAgon trial for advanced conventional chondrosarcoma. This rare bone cancer has no approved systemic therapies, so the positive data are significant. According to the company and press accounts, the trial met its primary endpoint with a statistically significant jump in progression-free survival (PFS) biospace.com. Patients on ozekibart lived a median 5.52 months without progression versus 2.66 months on placebo – a 52% reduction in the risk of progression or death biospace.com. All patient subgroups (including those with or without IDH mutations) saw benefit,
24 October 2025
 ·  ·  ·  ·  · 
Armata (ARMP) Stock Surges 150% After Breakthrough Bacteriophage Trial Results

Armata (ARMP) Stock Surges 150% After Breakthrough Bacteriophage Trial Results

Armata’s stock performance this week has been nothing short of dramatic. Prior to Oct. 22, ARMP had been trading in the low-$3 range (for example, it closed around $3.41 on Oct. 16 marketbeat.com). Once the late-breaking IDWeek data was announced, the shares rocketed – briefly hitting an intraday high near $16 (per some quotes) before settling at about $8.87 finviz.com investing.com. For context, that $8.87 close is the stock’s highest level in years (FinViz shows a 52-week high of only $3.50 prior to today). By midday on Oct. 22, Investing.com already noted the stock was up ~95% on the day
22 October 2025
 ·  ·  ·  · 
Arcturus Therapeutics Stock Soars to New High Then Crashes on Trial Data – What Investors Need to Know

Arcturus Therapeutics Stock Soars to New High Then Crashes on Trial Data – What Investors Need to Know

Stock Performance & Analyst Sentiment Arcturus stock had been riding a wave of positive sentiment through October 2025. On Oct 21 it closed at $23.16 – its highest level in a year marketbeat.com – following stronger-than-expected Q2 results (earnings beat and record revenue). However, on Oct 22 the company’s interim cystic fibrosis data triggered a dramatic sell-off. Investing.com reported that ARCT fell about 50% as investors digested the mixed news ng.investing.com. By pre-market trading the next day it was down over 60% at roughly $9 benzinga.com. MarketBeat confirmed that Guggenheim downgraded the stock to Neutral on Oct 22 marketbeat.com. Overall,
22 October 2025
 ·  ·  ·  ·  · 
Celcuity Stock Skyrockets 40% to Record High on ‘Practice-Changing’ Cancer Trial Results

Celcuity Stock Skyrockets 40% to Record High on ‘Practice-Changing’ Cancer Trial Results

Stock Soars on Positive Trial News Celcuity’s stock price skyrocketed on October 20, 2025 after the Minneapolis-based biotech reported game-changing clinical trial results. Shares jumped from around $52 to as high as $78–$81 intraday marketbeat.com, an approximately 40–50% single-day leap, before settling near a record high close. This surge marked a new 52-week high of $81.56 marketbeat.com and lifted Celcuity’s market capitalization above $2.2 billion investing.com. The stunning rally came on unusually heavy trading volume as investors rushed to buy shares, propelled by news from a major cancer conference. The immediate catalyst was Celcuity’s Phase 3 VIKTORIA-1 trial data presented over
20 October 2025
 ·  ·  ·  ·  · 
1 2
Go toTop